Submission of Intimation of Allotment of equity shares.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has allotted 23,20,000 equity shares at Rs. 60 each (face value Rs. 10, premium Rs. 50) through a preferential issue to the promoter group and non-promoter category, approved by the board on February 12, 2026. The company raised Rs. 13.92 crore from 36 allottees, including promoter Pavani Vupparapalli (3,25,000 shares) and several non-promoter investors. Post-allotment, paid-up equity capital has risen from Rs. 17.61 crore (1.76 crore shares) to Rs. 19.93 crore (1.99 crore shares), an increase of about 13.2% in share count. The allotment follows a special resolution passed by shareholders at an EGM on January 9, 2026, and BSE in-principle approval received on January 29, 2026.
The preferential allotment dilutes existing shareholders by roughly 13% and brings in Rs. 13.92 crore of fresh capital at a significant premium to face value. Existing shareholders should expect moderate share count expansion, and the stock could see short-term pressure depending on how the fresh capital is deployed by the company.